Isatuximab Provides 'Clinically Meaningful' OS Benefit in R/R Multiple Myeloma
Phase 3 results support isatuximab, pomalidomide, and dexamethasone as a standard of care for relapsed/refractory multiple myeloma, researchers say.
Source: oncologynurseadvisor.com